CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.
Flagyl is available in doses for adults as tablets of 250 mg, 500 mg, and 750 mg. The dose for pediatric patients is available as tablets of 35 to 50 mg/kg/24 hours. Patient dosage administration depends upon the severity of infection caused by parasites or bacteria, and any other existing medical conditions, particularly if they are severe. There are several drug interactions with Flagyl. Interactions, for example, like warfarin (Coumadin, Jantoven), cimetidine (Tagamet), cholestyramine (Questran, Questran Light), amprenavir (Agenerase), lithium (Eskalith, Lithobid), and cyclosporine. This medicine may cause increased heart rate, which can lead to seizures. Ask your doctor, pharmacist, or other medical professional if you have questions about Flagyl.
Adequate long-term studies in animals to evaluate carcinogenic potential have not been conducted with fluorouracil. In three in-vitro cell transformation assays, fluorouracil produced morphological transformation of cells. Morphological transformation was also produced in one of these in-vitro assays by a metabolite of fluorouracil and the transformed cells produced malignant tumors when injected into immunosuppressed syngeneic mice. Fluorouracil has been shown to exert mutagenic acitivity in the yeast cells, Bacillus subtilis and Drosophila assays. In addition, fluorouracil has produced chromosome damage at concentrations of and mcg/mL in an in vitro hamster fibroblast assay and increases in micronuclei formation in the bone marrow of mice at intraperitoneal doses within the human therapeutic dose range of 12-15 mg/kg/day. Patients receiving cumulative doses of - g of fluorouracil parenterally have shown an increase in numerical and structural chromosome aberrations in peripheral blood lymphocytes. Fluorouracil has been shown to impair fertility after parenteral administration in rats. In mice, single-dose intravenous and intraperitoneal injections of fluorouracil have been reported to kill differentiated spermatogonia and spermatocytes at a dose of 500 mg/kg and produce abnormalities in spermatids at 50 mg/kg.